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Abstract
Background: The prevalence of type 2 diabetes is increasing worldwide, accounting for 85-95% of all diagnosed
cases of diabetes. Clinical trials provide evidence of benefits of low-carbohydrate ketogenic diets in terms of clinical
outcomes on type 2 diabetes patients. However, the molecular events responsible for these improvements still
remain unclear in spite of the high amount of knowledge on the primary mechanisms of both the diabetes and
the metabolic state of ketosis. Molecular network analysis of conditions, diseases and treatments might provide
new insights and help build a better understanding of clinical, metabolic and molecular relationships among
physiological conditions. Accordingly, our aim is to reveal such a relationship between a ketogenic diet and type 2
diabetes through systems biology approaches.
Methods: Our systemic approach is based on the creation and analyses of the cell networks representing the
metabolic state in a very-low-carbohydrate low-fat ketogenic diet. This global view might help identify unnoticed
relationships often overlooked in molecule or process-centered studies.
Results: A strong relationship between the insulin resistance pathway and the ketosis main pathway was
identified, providing a possible explanation for the improvement observed in clinical trials. Moreover, the map
analyses permit the formulation of some hypothesis on functional relationships between the molecules involved in
type 2 diabetes and induced ketosis, suggesting, for instance, a direct implication of glucose transporters or
inflammatory processes. The molecular network analysis performed in the ketogenic-diet map, from the diabetes
perspective, has provided insights on the potential mechanism of action, but also has opened new possibilities to
study the applications of the ketogenic diet in other situations such as CNS or other metabolic dysfunctions.
Background
Novel approaches to study human disease networks
Efforts to link metabolic status or diseases by using sim-
ple, schematic biological pathways seldom offer the pos-
sibility to view the “broad picture”, and are rarely able
to explain the richness of the complex, redundant, intri-
cate and sometimes blurry nature of human metabolism.
Recently, the concept of “Diseaseome” [1] has arisen, as
an essay to conceptualize at the highest level the
relationship between observed phenotypes and underly-
ing molecular and physiological disease mechanisms or
disease cures. Although they are often treated separately,
most human diseases are not independent of each other.
Many diseases are associated with the breakdown of
functional modules (subnetworks) of a complex network
connecting many cellular components. Therefore, an
understanding of the functionally relevant genetic, regu-
latory, metabolic and protein-protein interactions will
play an important role in understanding the pathophy-
siology of human diseases [2].
Specifically, for studying human diseases from this
perspective, one has to use a Systems Biology or
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the construction of a complex network or map, where
nodes are usually proteins, and edges are relationships
between nodes. Relationships can be of any type: physi-
cal interaction between proteins, metabolic relationships
and relationships driven by signaling pathways, homol-
ogy or other characteristics. The physical representation
of this concept is a cell network that can be queried and
modeled to identify new complex pathways, or to iden-
tify previously unknown effectors of observable charac-
teristics, like for example new drug targets or new
metabolic relationships between mechanisms and path-
ways previously poorly understood [4,5].
In this work, we have applied these innovative con-
cepts to suggest potential metabolic and molecular rela-
tionships between the observed clinical improvements in
patients with type 2 diabetes and diet-induced ketosis.
Ketogenic diets
Since ketosis is the physiological response to fasting,
diets based on facilitating the ketosis status have been
popular to promote weight loss. The commonly called
ketogenic diets or very-low-carbohydrate diets (i.e. they
restrict carbohydrate intake sufficiently to cause ketosis)
include various diets that share in common a limit in
carbohydrate intake while they vary in the relative distri-
bution of protein, carbohydrate, and fat [6-8]. Low car-
bohydrate supply favors fatty acid oxidation, ketone
body production, and their utilization as an alternative
energy substrate, a metabolic state known as diet-
induced ketosis [9]. These diets contribute to maintain
the ketosis metabolic state during long periods of time,
producing a rapid and substantial decrease in body
weight in obese patients.
The benefits obtained from KD have been proposed as
a treatment for several pathologies [10,11]. A KD with a
high fat content has been used since 1920 for the treat-
ment of difficult-to-control seizures in children [12].
Recently, several clinical trials have confirmed its effi-
cacy [13]. Multiple theories have been proposed to
explain how the KD protects against seizures [14].
Gene-expression profiling studies have also been used in
order to identify the anticonvulsant mechanism of KD
[15,16]. These studies have shown that the KD produces
a coordinated up regulation of transcripts for genes
encoding proteins involved in energy metabolism in rat
hippocampus, including those specific to mitochondria.
Furthermore, ketone administration provides powerful
neuroprotection in various CNS injury animal models
[17] including: in vitro models of Alzheimer’s [18] and
Parkinson’s disease [19], in vitro glutamate toxicity [20]
and hypoxia [21]. All these intricate relationships high-
light the huge connectivity observed between apparently
unrelated biological processes which make systems
approaches, to understand the global functioning of the
individual, paramount.
Ketogenic diets show beneficial effects on diabetic
patients
Several clinical trials evaluating the effect of low-carbo-
hydrate diets in patients with type 2 diabetes consis-
tently showed improvements in glycemic control
[22,23]. In fact, diets with a low charge of carbohydrates
were used for the treatment of diabetes before insulin or
other medication therapies were available [24,25].
In particular low-carbohydrate ketogenic diets have
proved effective in improving glycemia and reducing
medications in patients with type 2 diabetes. Yancy et al.
in their study showed that Hemoglobin A1c (glycated
hemoglobin (HbA1c), which is considered as an index of
blood glucose control and the degree of oxidative stress
in diabetes) decreased by 16% and diabetes medications
were discontinued in 33% of the participants, reduced in
48% of the participants, and unchanged in 19% of the
participants [26]. Because this effect occurs immediately
upon implementing the dietary changes, individuals with
type 2 diabetes who are unable to adjust their own medi-
cation or self-monitor their blood glucose should not
make these dietary changes unless under close medical
supervision. The data presented in the study of Dashti et
al. showed that in addition to its therapeutic value, low
carbohydrate diet is safe to use for a longer period of
time in obese diabetics [27].
The improvements seen in the glycemic control of
diabetic patients following this type of diets are not only
attributable to a low-glycemic load as demonstrated in
the study of Westman et al [28]. They compared a low-
carbohydrate, ketogenic diet (LCKD) and a low-glycemic
index diet (LGID) on diabetic patients. The LCKD led
to greater improvements in glycemic control, and more
frequent medication reduction/elimination than a low-
glycemic index diet. In detail, the LCKD group had
greater improvements in hemoglobin A1c (-1.5% vs.
-0.5%, p = 0.03) and diabetes medications were reduced
or eliminated in 95.2% of LCKD vs. 62% of LGID parti-
cipants (p < 0.01). In fact, several authors point to a
direct effect of the ketone bodies in the improvements
seen in glucose levels [29,30].
Different variants of LCKD, like a very-low-carbohy-
drate low-fat ketogenic diet (protein-sparing modified
fast, PSMF), have reported similar outcomes in diabetic
patients [31].
Despite a history of clinical trials supporting the view
that the LCKD has a significant beneficial effect on sta-
bilizing hyperglycemia and ameliorating the diabetic
state, the underlying mechanisms implicated in this pro-
tective effect are not understood. In this sense, our aim
is to establish and evaluate the potential relationships, at
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and type 2 diabetes, by means of a highly innovative
network-based approach.
We have selected a very-low-carbohydrate low-fat
k e t o g e n i cd i e t( P S M F )a st h eb a s e sf o rt h ec o n s t r u c t i o n
of the map as it promotes a non-atherogenic lipid pro-
file compared to other type of ketogenic diets [32].
Methods
Construction of the ketosis status map
The first step in the construction of the cell network, or
map, representing the metabolic state of ketosis due to
protein-sparing modified fast consists in the identifica-
tion of all those proteins described to be important in
this particular metabolic state (i.e. seed proteins). With
this purpose, and to make sure that we do not overlook
any significant element, we have included in our ana-
lyses all molecules known to be related to the synthesis
and degradation of ketone bodies as well as those
involved in the amino acid metabolism, since it is
known that PSMF diets have an increased proportion of
protein respect to fat and carbohydrates. Pathway defini-
tions were those of the Kyoto Encyclopedia of Genes
and Genomes (KEGG) [33]. In particular, we selected all
those molecules involved in the following physiological
processes: hsa00071 Fatty acid metabolism; hsa00072
Synthesis and degradation of ketone bodies; hsa00100
Biosynthesis of steroids; hsa00230 Purine metabolism;
hsa00380 Tryptophan metabolism; hsa00400 Phenylala-
nine; tyrosine and tryptophan biosynthesis; hsa00591
Linoleic acid metabolism; hsa00910 Nitrogen metabo-
lism; hsa03320 PPAR signaling pathway; hsa04614;
Renin-angiotensin system hsa04930 Type II diabetes
mellitus). The map generation and extension process is
conducted in recursive steps through the incorporation
on the map of all known relationships of the seed pro-
teins described using public data bases (KEGG, REAC-
TOME, INTACT, BIOGRID) [33-36]. Relationships
used to create the network can be of three main types:
a) Physical interactions between proteins, known as
interactome, and b) Metabolic relationships between
proteins by sharing substrates, products and cofactors
associated to chemical reactions, known as metabolome,
and c) Relationships driven by signaling pathways,
homology relationships or other characteristics.
Analyzing the map
Anaxomics data base ax_SafetyDB is used to identify
proteins related to different physiological conditions
(syndrome, disease or pathological condition). It consists
of hand-curated data base that contains more than 160
characterized conditions. The physiological pathways for
each condition are identified and the proteins finally
responsible of the phenotypical effect determined. The
final responsible proteins for a phenotypical effect are
called effector proteins. For instance, the insulin-like
growth factor IB (IGF1) is a peptide hormone that is
expressed in most tissues, it shares significant structural
and functional similarities with insulin, and is implicated
in the pathogenesis of insulin resistance and cardiovas-
cular disease [37].
The final cell map is modeled as a direct connected
graph, known as network, where nodes are usually pro-
teins and edges (links) are relationships between nodes.
The resulting graph is strongly connected and depicts
complex cyclical structures. The pattern of connections
of each node to the rest of the nodes of the graph can
be seen as an “n” dimensional space with as many
dimensions as number of nodes.
Transforming the map into 2-dimensional images
For analyzing the relationship between proteins in the
map, it is necessary to analyze the number and types of
links between a given set of proteins. A conservative
nonlinear projection method to visualize high-dimen-
sional data into 2D has been applied. In this case a Mul-
tidimensional Scaling (MDS) transformation [38], is
used to reduce the number of dimensions of the map
into a 2 dimension (2D) to simplify the analysis. MDS
transformation depicts closer those proteins that are clo-
ser (less number of links) in the original map, taking
into account all possible ways to go from one to another
surfing over the map. The color grading of images gives
us an idea of the concentration of the different proteins
in our maps (i.e. proteins/pixel
2), from dark red
(low protein concentration) to white (high protein
concentration).
Presence, centrality and clustering analysis
The relationship between two groups of proteins of
interest (proteins related to ketosis and proteins related
with type 2 diabetes) was assessed by means of standard
measures in the field of biological networks, such as
presence, centrality or clustering analysis [39].
Presence analysis evaluates the number of proteins
present in the map in respect to the total number
of known proteins associated to a physiological condi-
tion as described in Anaxomics private data base
(ax_SafetyDB).
Centrality analysis evaluates if two groups of proteins
are or are not homogeneously distributed over 2D trans-
formation. The distance between groups was calculated
by Hausdorff distance [40]. This type of measurements
has been used before in systems biology field [41].
Clustering analysis allow the identification over 2D
transformations of regions enriched in proteins with
some remarkable characteristic, and is based on mea-
sures of protein density. The color grading of images
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protein density) to dark red (high protein density).
Results
The ketosis map has been built by using 447 seed pro-
t e i n sf r o mt h ek e t o s i sp a t h w a ya n dp r o t e i n sf r o mo t h e r
physiological pathways related to a protein-sparing mod-
ified fast (PSMF) a type of very-low-carbohydrate keto-
genic diet as described in Methods. The final map
includes 3,669 proteins and 142,531 known relation-
ships. We will refer to it as the ketogenic-diet map
(Figure 1A). Previous studies characterizing the effect of
ketogenic diets (KD) on gene expression profiling in the
hippocampus of rats identified up regulation of tran-
scripts encoding oxidative phosphorylation and other
mitochondrial proteins [15]. Some of the energy tran-
scripts identified by Bought et al study were also
reported in a previous microarray study of KD [16].
Most of the key gene identified in these gene expression
profiling studies are also present in our map. From the
26 energy metabolism genes that were up regulated in
the hippocampus of rats on a ketogenic diet, 18 have a
human ortholog present in our map. Indicating that our
map contains a comprehensive molecular description of
the main effects related with the ketogenic state.
Relationship at cell network level between the ketogenic-
diet map and diabetes
The main objective of thesea n a l y s e si st oi d e n t i f y
whether the molecular events responsible for diabetes
are indeed present, in a significant manner, in the keto-
genic-diet map. With this purpose, the relationship at
cell network level between the metabolic state of ketosis
and diabetes was assessed by presence, centrality and
clustering analysis. Type 2 Diabetes, as characterized in
ax_SafetyDB, includes 52 different effector proteins, 19
of which are present in the ketogenic-diet map, repre-
senting 36% of the total.
Centrality analysis gives us an idea of the topological
proximity at map level between diabetes and the ketosis
status. The most representative proteins for each of the
states are used for the measurement. The ketosis state
induced by protein-sparing modified fast is represented
by the 447 seed proteins, while diabetes is represented
by the 19 effector proteins present in the map. The dis-
tance (Hausdorff distance) between the two groups of
proteins of interest is of 1.5 jumps which is indicative of
a high topological proximity between the two physiolo-
gic effects studied, type 2 diabetes and the ketosis status.
To assess the statistical significance of this topological
proximity, we calculated the general distribution of
Hausdorff distances for each pair of physiological condi-
tions contained in our database (Figure 2A), finding that
a distance of 1.5 jumps, or fewer, is only observed by
5% of the motifs studied.
The clustering analysis identifies cores or groups of
effector proteins of diabetes present in the ketogenic-
diet map that are topologically relevant by MDS trans-
formation (Figure 1B).
Figure 1 Ketogenic diet map and type 2 diabetes. A) Ketogenic-
diet map by axPathNavigator™. Spheres represent proteins, lines are
relationships between proteins and green triangles indicate proteins
which are drug target. Seed proteins are colored in dark green.
B) Diabetes clusters on 2D projection of ketogenic-diet map
obtained through MDS transformation. The underling layer
represents the ketogenic-diet map, the color grading of the image
gives us an idea of the protein density, from black, no protein, until
yellow areas of high protein density, see adjunct scale left (protein/
pixel
2). The overlaying image shows the location and density of the
diabetes cluster on the ketogenic-diet map. Again, the color
grading of the image gives us an idea of the protein density in this
case from blue (low protein density) to dark red (high protein
density), see adjunct scale right (protein/pixel
2).
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ketogenic-diet map and diabetes
The next step is to address whether the macromolecular
components, constitutive of diabetes, identified in the
ketogenic-diet map are indeed related to type 2 diabetes,
as the clinical observations indicate. Accordingly, we
conducted similar analyses to those described above but,
this time, analyzing each of the type 2 diabetes patho-
physiological pathways (motives) independently. Two
different motives have been identified for type 2 diabetes
in ax_SafetyDB: insufficient insulin production and insu-
lin resistance.
The presence analysis indicates that the effector proteins
related to insulin resistance motive are found in greatest
amount in the ketogenic-diet map (13 representing a 56%
of all effector proteins for this specific pathway). See Table
1 for details.
The distance analysis between the proteins of the dif-
ferent KEGG pathways selected as seed proteins and the
proteins of the two physiological pathways related to
type 2 diabetes did not identify significant differences
between the pathways analyzed (data not shown), since
all KEGG pathways studied showed a close relationship
to both type 2 diabetes motives. The beneficial effects
of ketogenic diets observed in clinical studies on
patients with type 2 diabetes has been typically attribu-
ted to the low carbohydrate content of this type of
diets, and the concomitant weight loss. However, there
is still a significant beneficial contribution that cannot
be directly attributed to t h ep r e v i o u s l ym e n t i o n e d
aspects, and that some authors relate to the ketosis sta-
tus [25,29,30]. In order to explore this hypothesis
further, we have centered the analysis of distances and
relationships at a protein level on the two main path-
ways of the ketosis state: the synthesis and degradation
of ketone bodies and the fatty acid metabolism, and we
left for coming projects exploration of the relationships
with the other metabolic pathways used in the map
construction.
The distance analysis of the two main pathways of the
ketosis state used to construct the map (i.e. metabolism
of ketone bodies and fatty acids) are significantly closer
than what would be expected by chance to the patho-
physiological pathways related to type 2 diabetes, with
distances of 2.3 and 2.5 jumps, respectively (Table 2).
The calculated probability distribution of the Hausdorff
distances of all pathophysiological conditions contained
in ax_SafetyDB to the main ketosis state patways (71
and 72) indicates that distances minor or equal to 2.5
jumps are only seen in 15% of the cases and a distance
minor or equal to 2.3 jumps is only found in 5% of the
cases (Figure 2B).
The existence of nuclei or sets of diabetes effector
proteins from the two physiological pathways of type 2
diabetes that have a topological relationship on the map
Figure 2 Probability Density Function of Hausdorff distances.
The Hausdorff distance between any pair of physiological
conditions is calculated as the average number of jumps between
each protein contained in the first physiological condition against
the closest proteins in the second physiological condition and vice
versa. A) Probability Density Function of Hausdorff distances for any
pair of physiological conditions described in ax_SafetyDB. This
distribution shows the relation between all physiological conditions
contained in ax_SafetyDB. It comprises a total of 12,882
comparisons that give a normal distribution with an average
distance of 2.3 jumps and a standard deviation of 0.5 jumps. As can
be seen in the distribution 95% of the measures are greater than
1.5 jumps. B) Probability Density Function of Hausdorff distances for
all physiological conditions contained in ax_SafetyDB to the
ketogenic pathways (path 71 and 72). It comprises a total of 228
comparisons. As can be seen in the distribution 95% of the
measures are greater than 2.3 jumps.
Table 1 Relationship at metabolic pathway level between the ketogenic-diet map and type 2 diabetes
Ketogenic-diet map Pathophysiological pathways of Type 2 Diabetes
Presence Insufficient insulin production Insulin resistance
% effector proteins present in ketogenic-diet map
(No. protein present/Total No. in data base)
23% (7/30) 56% (13/23)
Distance to ketogenic pathways (Hausdorff distance) Insufficient insulin production Insulin resistance
Fatty acid metabolism (KEGG: HSA00071)
(No. of jumps, minimum distance)
2.3 (0.95) 2.5 (0.85)
Synthesis and degradation of ketone bodies (KEGG: HSA00072)
(No. of jumps, minimum distance)
2.3 (0.95) 2.5 (0.85)
Values in brackets report the significance of the distance value. It has been estimated from the distribution of the Hausdorff distances of all pathophysiological
conditions contained in ax_SafetyDB to pathways (path 71 and 72). The same principles as the ones described in figure 2 have been applied.
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level of clustering is found in proteins that define the
route of insulin resistance (Figure 3), concluding thus
that it is, indeed, this pathological process the one that
is the most embedded within the ketogenic-diet map.
Relationship at protein level between the ketogenic-diet
map and diabetes
The analysis of the relationship between effector pro-
teins of diabetes and seed proteins of ketogenic map
was also conducted. We found a total of 371 relation-
ships between seed proteins used to build the ketogenic-
diet map and diabetes effector proteins. Of those
relationships, 33 are direct, i.e., direct interaction estab-
lished between 8 diabetes proteins and 30 seed proteins
in the ketosis-map, notice that one protein can establish
more than one relation. From the 33 direct relationships
between type 2 diabetes and the seed proteins of the
ketosis map, 30 (88%) correspond to relations with pro-
teins of the insulin resistance pathway.
Among the 8 type 2 diabetes effector proteins which
establish direct relationships, there are 7 from the insu-
lin resistance pathway (SLC2A4, CBL, PRKCA, NFKB1,
IRS1, PPARGC1A and AKT3) and 1 from the insuffi-
cient insulin production pathway (GH1), see details of
the proteins involved in Table 2. From the 33 seed pro-
teins establishing direct relationships with diabetes pro-
teins we find 3 (ACAT1, ACOX1 and HADH1) from
the central routes of ketosis, synthesis and degradation
of ketone bodies and lipid metabolism. In summary, this
analysis of direct interactions at the protein level indi-
cates that type 2 diabetes motive, insulin resistance, is in
close relationship with proteins in the ketosis pathway
(Figure 4).
Discussion
Clinical trials provide evidence of benefits of very-low-
carbohydrate ketogenic diets in terms of clinical
outcomes of type 2 diabetes patients. Recently, advances
in systems biology and disease network analysis allow
new approaches to understand and reveal the complex
and intricate relationships between molecular network
and different metabolic phenotypes. In this sense, our
aim was to reveal such relationship between ketogenic
diet and type 2 diabetes by means of systems biology
methodologies, and specifically, by topological analysis
of the diabetes effector proteins in the ketogenic diet
molecular network map.
O u ra n a l y s i ss u g g e s t st h a t ,f r o mt h ei n n o v a t i v ep e r -
spective of the global topological analysis of molecular
networks describing the two conditions, the relationship
between the ketosis status induced by protein-sparing
modified fast and type 2 diabetes is closer to the insulin
resistance pathway than to insufficient insulin produc-
tion. Furthermore, the analysis at protein level shows
that 88% of the direct relationships between diabetes
effectors and the ketogenic-diet map are done by pro-
teins related to the insulin resistance pathway, while
proteins related to insufficient insulin production are
less present (Table 2).
Our studies at the protein level have identified that
one of the effector proteins of the insulin resistance
pathway, GLUT4, has a direct relation with proteins of
the fatty acids metabolism (HADH1 and ACOX1) a key
pathway of the ketogenic diet (Figure 3). GLUT4, Glu-
cose transporter type 4, facilitates glucose transport into
the cell in an insulin-responsive manner. Insulin
increases intracellular glucose concentration by transfer-
ring GLUT4 to the plasma membrane localization where
it exerts its function via vesicles that require acylated
lipid. HADH, encodes for the enzyme 3-hydroxyacyl-
coenzyme A dehydrogenase and catalyses the penultimate
reaction in the beta-oxidation of fatty acids. Defects in
HADH are the cause of familial hyperinsulinemic hypogly-
cemia type 4. It has been hypothesized that HADH
deficiency causes modulation of other genes associated
Table 2 Direct relationships (1 jump) between seed proteins of ketogenic-diet map and type 2 diabetes effector
proteins
Physiologic Pathway Type 2 Diabetes Effector Protein (Protein Name) Gene Name (synonyms)
Insufficient insulin
production
Somatotropin GH1
Solute carrier family 2, facilitated glucose transporter member 4 (GLUT4) SLC2A4 (GLUT4)
E3 ubiquitin-protein ligase CBL (CBL) CBL (CBL2, RNF55)
Protein kinase C alpha type (PRKCA) PRKCA (PKCA, PRKACA)
Insulin resistance Nuclear factor NF-kappa-B p105 subunit (NFKb) NFKB1
Insulin receptor substrate 1 (IRS-1) IRS1
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(PPARGC1-a)
PPARGC1A (LEM6, PGC1, PGC1A,
PPARGC)
Protein kinase Akt-3 (PKBg) AKT3 (PKBG)
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lin secretion [42], however, the mechanism remains
unclear [43].
Actually, the GLUT4- HADH interaction has been
anticipated earlier and a role in priming fatty acids for
protein acylation by adjusting acyl chain length by b-
oxidation has been proposed [44]. The interaction may
be part of the regulatory mechanisms that modulate the
catalytic activity of GLUT4 or it could participate on the
recycling between stocks and functional storage in the
membrane.
On the other hand, the direct relationship of GLUT4
with ACOX1, Peroxisomal acylcoenzyme A oxidase 1,
seems unfeasible as this enzyme is located in the peroxi-
some while GLUT4 resides in the cytoplasm or asso-
ciated to the membrane.
The analysis at the molecular level also provided
another provable way in which ketone bodies and insu-
lin resistance can be related. We found CBL and NFKb,
two proteins related with insulin resistance and also
with inflammation at two jumps distance from the mito-
chondrial (ACAT1) and cytosolic (ACAT2) form of
acetyl-CoA acetiltransferase, an enzyme of lipid metabo-
lism involved on the fatty acids metabolism and the
synthesis and degradation of ketone bodies.
Conditions in which inflammatory cytokines are ele-
vated insulin resistance has also been shown to occur
[29]. Ketone bodies reportedly counteract certain
inflammatory processes by blocking the proinflamma-
tory cytokine, macrophage migration inhibitory factor
(MIF) [45]. The high glucose levels that occur in insulin
resistance states, oxidize the low-density lipoproteins
which in turn have been shown to activate NF-Kb and
induce MIF expression, in vascular smooth muscle cells
[46].
NFKb is a drug target for drugs designed to reduce
inflammatory processes associated with type 2 diabetes
[47]. In a first step NFKb is related to TRAF6 and
KAT5. KAT5 is the catalytic subunit of NuA4 histone
acetyltransferase complex that is involved in the acetyla-
tion of nucleosomal histone H4 and H2A producing an
activation of transcription of selected genes. No previous
relation with bodies or lipid metabolism has been
Figure 3 Clusters of the different type 2 diabetes motifs on a
2D projection of ketogenic-diet map. The underlying image
represents the ketogenic-diet map obtained through MDS
transformation. The color grading of the image gives us an idea of
the protein density, from black, no protein, until yellow areas of
high protein density. Overlaying this image the localization of the
protein clusters for the different type 2 diabetes motifs is presented.
The color grading of images gives us an idea of the protein density
from dark red (high-density proteins) to blue (low-density of
proteins) (protein/pixel
2).
Figure 4 Protein relationship between effector proteins
involved in the insufficient insulin production motive of
diabetes and the key pathways of the ketogenic diet. Two
complementary hypothesis of functional relationship between the
molecules involved in both physiological processes have evolved:
a) Elements of lipid metabolism may facilitate proper cellular
localization of glucose transporter and recycling and b) Ketone
bodies can alleviate certain inflammatory processes by blocking
specific cytokines.
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cation has shown that TRAF6, an adapter protein for
the TNF receptor and interleukin-1R receptor, has a
role in immunity by modulating fatty acid metabolism
[48]. These set of relations offer another feasible way by
which ketone bodies palliate the effects of elevated insu-
lin resistance states.
CBL is an E3 ubiquitin-protein ligase involved on glu-
cose uptake stimulated by insulin. Its inhibition is asso-
ciated with insulin resistance [49]. We also found a
direct interaction of CBL with TRAF6, which in turn
links CBL with ACAT1 and ACAT2, enzymes of lipid
metabolism involved on the fatty acids metabolism and
the synthesis and degradation of ketone bodies.
Finally, it is worth stressing that neither of the hypoth-
eses raised by our approach relates the beneficial effects
described in type 2 diabetes with the significant weight
loss achieved as a consequence of the diet itself, which
correlates well with clinical observations that uncouple
these two effects, since the improvements in the glyce-
mic state are detected before a significant reduction of
weight.
Conclusions
The global molecular network analysis of conditions,
diseases and treatments (either pharmacological or
based in changes in life style) are bound to provide new
insights and help in a better understanding of clinical,
metabolic, and molecular relationships between them.
The analysis of the ketogenic-diet map from the dia-
betes perspective offers interesting results and insights
on the mechanism of action, but also opens new possi-
bilities to study the applications of the ketogenic diet in
other situations such as CNS or other metabolic dys-
functions. The strong relationship identified in our stu-
dies between the insulin resistance pathway and the
ketogenic diet provides a plausible explanation for the
improvement observed on clinical trials from a new and
different perspective. Moreover, the map analysis high-
lights two complementary hypothesis of functional rela-
tionship between the molecules involved in both
physiological processes: a) Elements of lipid metabolism
may facilitate proper cellular localization of glucose
transporter and recycling and b) Ketone bodies can alle-
viate certain inflammatory processes by blocking specific
cytokines. Although our studies incorporate the most
actual data on the field, this is a fast evolving field thus
additional or complementary mechanisms can come
into view as novel data on this physiological condition
emerges.
The characterization and analyses of protein networks
is indeed becoming a cornerstone in modern biology,
with clear biomedical applications [4,5,50,51]. However,
network and systems biology approaches are still in
their infancy and will have to certainly overcome many
caveats, mostly related to the quality of the data and its
interpretation. For instance, we can assess the reliability
of the relationship between molecules that have been
described but, obviously, cannot say anything about the
many thousands that are yet to be discovered. On the
other hand, to be most valuable, the functional hints
coming from global analyses, such as the potential
relationships reported in this study, will need to be
individually validated. We anticipate that large interna-
tional efforts, such as the ongoing initiatives to chart
disease-related interaction maps [52], will soon permit
to generate the basic wiring inherent to most physio-
pathological processes and refine systems biology
models to the point where they can be effectively
applied to biomedicine.
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